Kalvista Pharmaceuticals

Yahoo Finance • 18 days ago

KalVista prices upsized offering of $125M of 3.250% notes due 2031

* KalVista Pharmaceuticals (NASDAQ:KALV [https://seekingalpha.com/symbol/KALV]) announced [https://seekingalpha.com/pr/20243780-kalvista-prices-upsized-offering-of-125_0-million-of-3_250-percent-convertible-senior-notes] on Wednesday the... Full story

Yahoo Finance • 18 days ago

KalVista to offer $110M in convertible notes; shares down 10%

* KalVista Pharmaceuticals (NASDAQ:KALV [https://seekingalpha.com/symbol/KALV]) plans to offer $110M in convertible senior notes due 2031 via private placement. * An additional $15M in notes may be issued if initial purchasers exercise... Full story

Yahoo Finance • last month

Stocks Rally and Bond Yields Fall on Fed Rate Cut Hopes

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.66%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • last month

Stocks Climb as US Labor Market Weakness Bolsters Fed Rate Cut Expectations

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.22%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • last month

KalVista Pharmaceuticals Inc (NASDAQ:KALV) Stock Rises 7.4% on Strong EKTERLY Launch Despite Q1 Earnings Miss

KalVista Pharmaceuticals Inc (NASDAQ:KALV [https://www.chartmill.com/stock/quote/KALV/profile]) reported its fiscal first-quarter 2026 financial results, delivering revenue that fell short of analyst expectations while posting a wider-than... Full story

Yahoo Finance • last month

KalVista Pharmaceuticals GAAP EPS of -$1.12 misses by $0.17, revenue of $1.43M misses by $0.66M

* KalVista Pharmaceuticals press release [https://seekingalpha.com/pr/20229221-kalvista-pharmaceuticals-provides-operational-update-and-reports-fiscal-quarter-financial] (NASDAQ:KALV [https://seekingalpha.com/symbol/KALV]): Q1 GAAP EPS o... Full story

Yahoo Finance • last month

Stocks Rise Before the Open With Key U.S. Inflation Data in Focus

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are up +0.16%, and September Nasdaq 100 E-Mini futures (NQU25 [https://www.barchart.com/futures/quotes/NQU25/overview]) are up +0.15% this morning as... Full story

Yahoo Finance • last month

Stocks Supported as Easing Price Pressures Reinforce Fed Rate Cut Hopes

The S&P 500 Index ($SPX) (SPY) on Wednesday closed up +0.30%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.48%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.04%.  September E-mini S&P futures (ESU25) rose +0.28%, and... Full story

Yahoo Finance • last month

Stocks Turn Lower on Economic Concerns after Weak US Unemployment Report

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is down -0.56%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures... Full story

Yahoo Finance • last month

Stocks Mixed after Weak US Unemployment Report Bolsters Case for Multiple Fed Rate Cuts

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is down -0.11%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures... Full story

Yahoo Finance • last month

Stocks Higher as Weak US Unemployment Report Bolsters Case for Multiple Fed Rate Cuts

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.83%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • last month

Stocks Supported by Fed Rate Cut Expectations

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Thursday rose +0.84%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futu... Full story

Yahoo Finance • 2 months ago

KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82

On Wednesday, KalVista Pharmaceuticals stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 82, up from 79 the day before. Is KalVista Pharmaceutic... Full story

Yahoo Finance • 3 months ago

JMP reiterates Market Outperform rating on Kalvista stock after UK approval

Investing.com - JMP Securities has reiterated its Market Outperform rating and $27.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), currently trading at $15.17, following UK approval of the company’s HAE treatment. The target... Full story

Yahoo Finance • 3 months ago

KalVista gets UK nod for Ekterly

[Blue Capsules on Conveyor at Modern Pharmaceutical Factory. Tablet and Capsule Manufacturing Process. Close-up Shot of Medical Drug Production Line.] SweetBunFactory/iStock via Getty Images * KalVista Pharmaceuticals (NASDAQ:KALV [http... Full story

Yahoo Finance • 3 months ago

Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label

Investing.com - H.C. Wainwright has reiterated a Buy rating and $27.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), representing a 74% upside from the current price of $15.51, following the FDA approval of its hereditary ang... Full story

Yahoo Finance • 3 months ago

Kalvista Pharma CEO Palleiko sells $517k in shares

Benjamin L. Palleiko, Chief Executive Officer of KalVista Pharmaceuticals (NASDAQ:KALV), sold 32,979 shares of common stock on July 9, 2025, at a price of $15.6925, for a total transaction value of $517,522. The sale comes as the stock tra... Full story

Yahoo Finance • 3 months ago

Kalvista Pharma chief development officer sells $474k in shares

Yea Christopher, Chief Development Officer of KalVista Pharmaceuticals Inc (NASDAQ:KALV), sold 30,250 shares of common stock on July 9, 2025, at a price of $15.6925, totaling $474,698. The sale comes as the stock trades near its 52-week hi... Full story

Yahoo Finance • 3 months ago

Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins

Investing.com - Leerink Partners has reiterated an Outperform rating and $20.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ:KALV) following the company’s fiscal fourth-quarter 2025 financial results and corporate update. The stock... Full story

Yahoo Finance • 3 months ago

KalVista price target raised to $37 from $22 at BofA

BofA raised the firm’s price target on KalVista (KALV) to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary angioedema attacks with a broad label and... Full story